Chow Kit May, Sumugam Kala, Ahmad Amali
Department of Ophthalmology, Hospital Kuala Lumpur, Kuala Lumpur, MYS.
Department of Radiology, Hospital Kuala Lumpur, Kuala Lumpur, MYS.
Cureus. 2024 Dec 12;16(12):e75613. doi: 10.7759/cureus.75613. eCollection 2024 Dec.
This retrospective case series evaluates the use of intralesional bleomycin injections in treating orbital venolymphatic malformations (OVLM). Three patients, a 7-year-old girl, a 37-year-old woman, and a 56-year-old man, presented with OVLM where the first two were recurrent cases with a history of failed sclerotherapy. All patients received multiple doses of intralesional bleomycin injections, resulting in significant reductions in lesion size, decreased proptosis, and pain relief. Although complete symptom resolution was not achieved, the injections were well-tolerated, and no ophthalmic or systemic side effects were reported. The findings suggest that bleomycin, a sclerosing agent inducing local inflammation and thrombosis, is an effective and safe treatment for OVLM, particularly in cases where excision is not feasible or previous therapies have failed. Intralesional bleomycin injections may offer a valuable alternative for managing this challenging condition.
本回顾性病例系列评估了病灶内注射博来霉素治疗眼眶静脉淋巴管畸形（OVLM）的疗效。三名患者，一名7岁女孩、一名37岁女性和一名56岁男性，均患有OVLM，其中前两名是复发病例，有硬化治疗失败史。所有患者均接受了多剂量的病灶内博来霉素注射，结果病变大小显著减小，眼球突出减轻，疼痛缓解。虽然未实现症状完全缓解，但注射耐受性良好，未报告眼部或全身副作用。研究结果表明，博来霉素作为一种可诱导局部炎症和血栓形成的硬化剂，是治疗OVLM的一种有效且安全的方法，尤其是在无法进行切除或先前治疗失败的情况下。病灶内注射博来霉素可能为处理这一具有挑战性的病症提供一种有价值的替代方法。
